AP

Can cancer blood tests live up to promise of saving lives?

Apr 10, 2022, 10:16 PM | Updated: Apr 15, 2022, 9:26 am

Joyce Ares sits for a portrait in the dinning room of her home on Friday, March 18, 2022, in Canby,...

Joyce Ares sits for a portrait in the dinning room of her home on Friday, March 18, 2022, in Canby, Ore. When she turned 74, Ares was feeling fine when she agreed to give a blood sample for research. So she was surprised when the screening test came back positive for signs of cancer. After a repeat blood test, a PET scan and a needle biopsy, she was diagnosed with Hodgkin lymphoma. (AP Photo/Nathan Howard)

(AP Photo/Nathan Howard)

Joyce Ares had just turned 74 and was feeling fine when she agreed to give a blood sample for research. So she was surprised when the screening test came back positive for signs of cancer.

After a repeat blood test, a PET scan and a needle biopsy, she was diagnosed with Hodgkin lymphoma.

“I cried,” the retired real estate broker said. “Just a couple of tears and thought, ‘OK, now what do we do?'”

The Canby, Oregon, resident had volunteered to take a blood test that is being billed as a new frontier in cancer screening for healthy people. It looks for cancer by checking for DNA fragments shed by tumor cells.

Such blood tests, called liquid biopsies, are already used in patients with cancer to tailor their treatment and check to see if tumors come back.

Now, one company is promoting its blood test to people with no signs of cancer as a way to detect tumors in the pancreas, ovaries and other sites that have no recommended screening method.

It’s an open question whether such cancer blood tests — if added to routine care — could improve Americans’ health or help meet the White House’s goal of cutting the cancer death rate in half over the next 25 years.

With advances in DNA sequencing and data science making the blood tests possible, California-based Grail and other companies are racing to commercialize them.

And U.S. government researchers are planning a large experiment — with 200,000 participants and possibly lasting seven years — to see if the blood tests can live up to the promise of catching more cancers earlier and saving lives.

“They sound wonderful, but we don’t have enough information,” said Dr. Lori Minasian of the National Cancer Institute, who is involved in planning the research. “We don’t have definitive data that shows that they will reduce the risk of dying from cancer.”

Grail is far ahead of other companies with 2,000 doctors willing to prescribe the $949 test. Most insurance plans don’t cover the cost. The tests are being marketed without endorsements from medical groups or a recommendation from U.S. health authorities.

FDA authorization, clearance or approval of such tests is required by law, but the agency historically has not enforced most regulatory requirements for ones – like Grail’s – that are designed, manufactured and used within a single laboratory. The agency is working with Congress on legislation to update the regulatory framework, which would include active oversight for such tests, said FDA spokesman Jim McKinney.

“For a drug, the FDA demands that there is a substantial high likelihood that the benefits not only are proven, but they outweigh the harms. That’s not the case for devices like blood tests,” said Dr. Barry Kramer of the Lisa Schwartz Foundation for Truth in Medicine.

Grail plans to seek approval from the FDA, but is marketing its test as it submits data to the agency.

The history of cancer screening has taught caution. In 2004, Japan halted mass screening of infants for a childhood cancer after studies found it didn’t save lives. Last year, a 16-year study in 200,000 women in the United Kingdom found regular screening for ovarian cancer didn’t make any difference in deaths.

Cases like these have uncovered some surprises: Screening finds some cancers that don’t need to be cured. The flip side? Many dangerous cancers grow so fast they elude screening and prove deadly anyway.

And screening can do more harm than good. Anxiety from false positives. Unnecessary costs. And serious side effects from cancer care: PSA tests for men can lead to treatment complications such as incontinence or impotence, even when some slow-growing prostate cancers would never have caused trouble.

The evidence is strongest for screening tests for cancers of the breast, cervix and colon. For some smokers, lung cancer screening is recommended.

The recommended tests — mammography, PAP tests, colonoscopy — look for one cancer at a time. The new blood tests look for many cancers at once. That’s an advantage, according to Grail executive Dr. Joshua Ofman.

“We screen for four or five cancers in this country, but (many) cancer deaths are coming from cancers that we’re not looking for at all,” Ofman said.

Dr. Tomasz Beer of Oregon Health & Science University in Portland led the company-sponsored study that Joyce Ares joined in 2020. After a miserable winter of chemotherapy and radiation, doctors told her the treatment was a success.

Her case isn’t an outlier, “but it is the sort of hoped-for ideal outcome, and not everyone is going to have that,” Beer said.

While there were other early cancers detected among study participants, some had less clear-cut experiences. For some, blood tests led to scans that never located a cancer, which could mean the result was a false positive, or it could mean there’s a mystery cancer that will show up later. For others, blood tests detected cancer that turned out to be advanced and aggressive, Beer said. One older participant with a bad case declined treatment.

Grail continues to update its test as it learns from these studies, and is sponsoring a trial with Britain’s National Health Service in 140,000 people to see if the blood test can reduce the number of cancers caught in late stages.

Although Ares feels lucky, it’s impossible to know whether her test added healthy years to her life or made no real difference, said Kramer, former director of the National Cancer Institute’s Division of Cancer Prevention.

“I sincerely hope that Joyce benefited from having this test,” Kramer said when told of her experience. “But unfortunately, we can’t know, at the individual Joyce level, whether that’s the case.”

Cancer treatments can have long-term side effects, he said, “and we don’t know how fast the tumor would have grown.” Treatment for Hodgkin lymphoma is so effective that delaying therapy until she felt symptoms might have achieved the same happy outcome.

For now, health experts stress the Grail blood test is not a cancer diagnosis; a positive result triggers further scans and biopsies.

“This is a path in diagnostic testing that has never been tried before,” Kramer said. “Our ultimate destination is a test that has a clear net benefit. If we don’t do it carefully, we’ll go way off the path.”

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

___

This story was first published on April 11, 2022. It was updated on April 14, 2022, to make clear that FDA approval of some tests is required by law but the agency historically has not enforced regulatory requirements on certain tests.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


              Vials of blood from a participant in a clinical study of the effectiveness of a new liquid biopsy technology are packaged for shipment at Oregon Health & Science University in Portland, Ore., on March 14, 2022. The clinical trial will follow hundreds of participants for three years to see if signals of any cancers that participants later develop were present in their blood. (AP Photo/Gillian Flaccus)
            
              Jacob Marquez, a clinical research coordinator at Oregon Health & Science University's Knight Cancer Institute in Portland, Ore., draws blood from clinical study participant David Parker on March 14, 2022. Parker is one of hundreds of people participating in a trial for a new liquid biopsy technology that could detect early signs of cancer in a person's blood. (AP Photo/Gillian Flaccus)
            
              Jacob Marquez, a clinical research coordinator at Oregon Health & Science University's Knight Cancer Institute in Portland, Ore., draws blood from a clinical study participant on March 14, 2022. Parker is one of hundreds of people participating in a trial for a new liquid biopsy technology that could detect early signs of cancer in a person's blood. (AP Photo/Gillian Flaccus)
            
              Joyce Ares checks on daffodils in her back garden on Friday, March 18, 2022, in Canby, Ore. She had volunteered to take a blood test that is being billed as a new frontier in cancer screening for healthy people. It looks for cancer by checking for DNA fragments shed by tumor cells. (AP Photo/Nathan Howard)
            
              Joyce Ares stands for a portrait in front of her home on Friday, March 18, 2022, in Canby, Ore. She had volunteered to take a blood test that is being billed as a new frontier in cancer screening for healthy people. It looks for cancer by checking for DNA fragments shed by tumor cells. (AP Photo/Nathan Howard)
            
              Joyce Ares plants a peony bud in her garden on Friday, March 18, 2022, in Canby, Ore. She had volunteered to take a blood test that is being billed as a new frontier in cancer screening for healthy people. It looks for cancer by checking for DNA fragments shed by tumor cells. (AP Photo/Nathan Howard)
            
              Joyce Ares plays with her poodles Gracie, left, and Oliver in the dinning room of her home on Friday, March 18, 2022, in Canby, Ore. She had volunteered to take a blood test that is being billed as a new frontier in cancer screening for healthy people. It looks for cancer by checking for DNA fragments shed by tumor cells. (AP Photo/Nathan Howard)
            
              Joyce Ares sits for a portrait in the dinning room of her home on Friday, March 18, 2022, in Canby, Ore. Although Ares feels lucky, it’s impossible to know whether her cancer blood test added healthy years to her life or made no real difference, said Dr. Barry Kramer , former director of the National Cancer Institute’s Division of Cancer Prevention. “I sincerely hope that Joyce benefited from having this test,” Kramer said when told of her experience. Cancer treatments can have long-term side effects, he said, "and we don’t know how fast the tumor would have grown.” Treatment for Hodgkin lymphoma is so effective that delaying therapy until she felt symptoms might have achieved the same happy outcome. (AP Photo/Nathan Howard)
            
              Joyce Ares grooms her poodle Gracie in the garage on Friday, March 18, 2022, in Canby, Ore. She had volunteered to take a blood test that is being billed as a new frontier in cancer screening for healthy people. It looks for cancer by checking for DNA fragments shed by tumor cells. (AP Photo/Nathan Howard)
            
              Joyce Ares and her poodle Oliver water a recently-planted peony in her back garden on Friday, March 18, 2022, in Canby, Ore. She had volunteered to take a blood test that is being billed as a new frontier in cancer screening for healthy people. It looks for cancer by checking for DNA fragments shed by tumor cells. (AP Photo/Nathan Howard)
            
              Joyce Ares sits for a portrait in the dinning room of her home on Friday, March 18, 2022, in Canby, Ore. When she turned 74, Ares was feeling fine when she agreed to give a blood sample for research. So she was surprised when the screening test came back positive for signs of cancer. After a repeat blood test, a PET scan and a needle biopsy, she was diagnosed with Hodgkin lymphoma. (AP Photo/Nathan Howard)

AP

A demonstrator in Tel Aviv holds a sign calling for a cease-fire in the Hamas-Israel war on Nov. 21...

Associated Press

Hamas releases a third group of hostages as part of truce, and says it will seek to extend the deal

The fragile cease-fire between Israel and Hamas was back on track Sunday as the first American was released under a four-day truce.

4 days ago

Men look over the site of a deadly explosion at Al-Ahli Hospital in Gaza City, Wednesday, Oct. 18, ...

Associated Press

New AP analysis of last month’s deadly Gaza hospital explosion rules out widely cited video

The Associated Press is publishing an updated visual analysis of the deadly Oct. 17 explosion at Gaza's Al-Ahli Hospital.

7 days ago

Peggy Simpson holds a photograph of law enforcement carrying Lee Harvey Oswald's gun through a hall...

Associated Press

JFK assassination remembered 60 years later by surviving witnesses to history, including AP reporter

Peggy Simpson is among the last surviving witnesses who are sharing their stories as the nation marks the 60th anniversary.

7 days ago

Israeli Prime Minister Benjamin Netanyahu, chairs the weekly cabinet meeting in Jerusalem, Sunday, ...

Associated Press

Israeli Cabinet approves cease-fire with Hamas; deal includes release of 50 hostages

Israel’s Cabinet on Wednesday approved a cease-fire deal with the Hamas militant group that would bring a temporary halt to a devastating war.

8 days ago

Republican presidential candidate and former President Donald Trump helps serve food to Texas Natio...

Associated Press

Trump receives endorsement from Texas Gov. Greg Abbott during a visit to a US-Mexico border town

Donald Trump picked up the Texas governor’s endorsement Sunday during a visit to a U.S.-Mexico border town.

10 days ago

Eric Trump, executive vice president of Trump Organization Inc., speaks to the media as he leaves f...

Associated Press

Lawyers in Trump’s civil fraud trial are ordered to clam up about judge’s communications with staff

Eric Trump testified Friday that he was relying on accountants to ensure the accuracy of financial statements.

26 days ago

Sponsored Articles

...

Dierdre Woodruff

Interest rates may have peaked. Should you buy a CD, high-yield savings account, or a fixed annuity?

Interest rates are the highest they’ve been in decades, and it looks like the Fed has paused hikes. This may be the best time to lock in rates for long-term, low-risk financial products like fixed annuities.

Follow @KTAR923...

The 2023 Diamondbacks are a good example to count on the underdog

The Arizona Diamondbacks made the World Series as a surprise. That they made the playoffs at all, got past the Milwaukee Brewers in the NL Wild Card round, swept the Los Angeles Dodgers in the NLDS and won two road games in Philadelphia to close out a full seven-game NLCS went against every expectation. Now, […]

...

Desert Institute for Spine Care

Desert Institute for Spine Care (DISC) wants to help Valley residents address back, neck issues through awake spine surgery

As the weather begins to change, those with back issues can no longer rely on the dry heat to aid their backs. That's where DISC comes in.

Can cancer blood tests live up to promise of saving lives?